Jacobs IJ - Search Results

1

The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D, Dobbs S, Godfrey K, Herod J, Leeson S, Mould T, Murdoch J, Oram D, Scott I, Seif MW, Williamson K, Woolas R, Fallowfield L, Campbell S, Skates SJ, Parmar M, Jacobs IJ. Menon U, et al. Among authors: jacobs ij. Br J Cancer. 2017 Aug 22;117(5):619-627. doi: 10.1038/bjc.2017.222. Epub 2017 Jul 25. Br J Cancer. 2017. PMID: 28742794 Free PMC article.

2

Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.

Jacobs IJ, Oram DH, Bast RC Jr. Jacobs IJ, et al. Obstet Gynecol. 1992 Sep;80(3 Pt 1):396-9. Obstet Gynecol. 1992. PMID: 1495694

3

Early diagnosis of ovarian cancer.

Oram DH, Jacobs IJ, Brady JL, Prys-Davies A. Oram DH, et al. Among authors: jacobs ij. Br J Hosp Med. 1990 Nov;44(5):320, 322, 324. Br J Hosp Med. 1990. PMID: 2275994 Review.

4

Serum levels of CA 125 during the first trimester of normal outcome, ectopic and anembryonic pregnancies.

Jacobs IJ, Fay TN, Yovich J, Stabile I, Frost C, Turner J, Oram DH, Grudzinskas JG. Jacobs IJ, et al. Hum Reprod. 1990 Jan;5(1):116-22. doi: 10.1093/oxfordjournals.humrep.a137030. Hum Reprod. 1990. PMID: 2324241

5

The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women.

Jacobs IJ, Fay TN, Stabile I, Bridges JE, Oram DH, Grudzinskas JG. Jacobs IJ, et al. Br J Obstet Gynaecol. 1988 Nov;95(11):1190-4. doi: 10.1111/j.1471-0528.1988.tb06798.x. Br J Obstet Gynaecol. 1988. PMID: 3207648

6

Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.

Jacobs IJ, Rivera H, Oram DH, Bast RC Jr. Jacobs IJ, et al. Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4. doi: 10.1111/j.1471-0528.1993.tb15177.x. Br J Obstet Gynaecol. 1993. PMID: 8297846

7

Elevation of multiple serum markers in patients with stage I ovarian cancer.

Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC Jr. Woolas RP, et al. Among authors: jacobs ij. J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51. doi: 10.1093/jnci/85.21.1748. J Natl Cancer Inst. 1993. PMID: 8411259

8

Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.

Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB. Hurteau JA, et al. Among authors: jacobs ij. Cancer. 1995 Nov 1;76(9):1615-20. doi: 10.1002/1097-0142(19951101)76:9<1615::aid-cncr2820760918>3.0.co;2-g. Cancer. 1995. PMID: 8635066 Clinical Trial.

9

Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study.

Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, Sibley K, Oram DH. Jacobs IJ, et al. BMJ. 1996 Nov 30;313(7069):1355-8. doi: 10.1136/bmj.313.7069.1355. BMJ. 1996. PMID: 8956699 Free PMC article. Clinical Trial.

10

No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.

Ryan A, Al-Jehani RM, Mulligan KT, Jacobs IJ. Ryan A, et al. Among authors: jacobs ij. Gynecol Oncol. 1998 Jan;68(1):14-7. doi: 10.1006/gyno.1997.4881. Gynecol Oncol. 1998. PMID: 9454653

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

265 results

Search Page